Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1–34
J. Clin. Invest. Dengshun Miao, et al. 115:2402 doi:10.1172/JCI24918 [Go to this article.]

Figure 3
Osteoblast-specific Pthrp ablation reduces BMD and trabecular bone volume. (A–C) Serum calcium (A), 1,25(OH)₂D₃ (B), and PTH (C) were measured as described in Methods. White bars, Pthrp^flox/flox mice; black bars, Pthrp^flox/flox;cre^ColI mice. Data are shown as mean ± SEM. (D) Parathyroid gland histology was assessed from paraffin sections of thyroparathyroidal tissue stained with H&E. Magnification, ×200. (E) Faxitron radiographs of femur and tibia. (F) Three-dimensional reconstruction of the proximal tibiae from μCT scans. (G) Micrographs from undecalcified sections of the proximal end of tibia stained with the von Kossa procedure. Magnification, ×25. (H) BMD measurements at femurs and tibiae. (I–L) Quantitative histomorphometry for BV/TV (I), trabecular number (Tb.N) (J), trabecular thickness (Tb.Th) (K), and trabecular separation (L). Data shown represent mean ± SEM of 5–6 animals per group. *P < 0.05 and **P < 0.01 for Pthrp^flox/flox;cre^ColI (black bars) versus Pthrp^flox/flox control mice (white bars).